A Phase II Study to Evaluate the Efficacy and Safety of Selinexor in Patients With Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs Selinexor (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Acronyms ESSENTIAL
- 14 Mar 2019 Planned End Date changed from 1 Nov 2023 to 14 Mar 2025.
- 14 Mar 2019 Planned primary completion date changed from 1 Nov 2023 to 14 Mar 2024.
- 14 Mar 2019 Status changed from not yet recruiting to recruiting.